II-IIIB
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC (NCT06897046) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-07-30 |
Track II-IIIB automatically
Every clearance here is in the API, with alerts when new ones post.